Immune checkpoint inhibitors (ICIs), such as Atezolizumab (one of the anti-PD-L1 drugs), are now the preferred treatment for patients with unresectable HCC, which show good efficiency than chemotherapy or targeted therapies[5]. Here, CD274 is linked to hepatocellular carcinoma.